Impaired cardiac mitochondrial oxidative phosphorylation and enhanced mitochondrial oxidative stress in feline hypertrophic cardiomyopathy

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 308, Issue 10, 2015, Pages H1237-H1247

  Christiansen, Liselotte B ^a   Dela, Flemming ^a   Koch, Jørgen ^a   Hansen, Christina N ^a   Leifsson, Pall S ^a   Yokota, Takashi ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Hypertrophic cardiomyopathy; Mitochondria; Oxidative stress

Indexed keywords

ADENOSINE DIPHOSPHATE; FATTY ACID; GLUTAMIC ACID; MALIC ACID; MEDIUM CHAIN FATTY ACID; PYRUVIC ACID; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOMESTIC CAT; ENZYME ACTIVITY; FEMALE; HEART MITOCHONDRION; HEART MUSCLE; HISTOPATHOLOGY; HYPERTROPHIC CARDIOMYOPATHY; MAINE COON CAT; MALE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; SKELETAL MUSCLE; ANIMAL; CAT; HEART MUSCLE CELL; METABOLISM;

ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; CATS; FEMALE; MALE; MITOCHONDRIA, HEART; MUSCLE FIBERS, SKELETAL; MYOCYTES, CARDIAC; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS;

EID: 84930862762     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00727.2014     Document Type: Article

References (57)

1. Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, Maher AR, Kaur K, Taylor J, Henning A, Ashrafian H, Watkins H, Frenneaux M. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122: 1562–1569, 2010.
2. Ashrafian H, Redwood C, Blair E, Watkins H. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet 19: 263–268, 2003.
3. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell 120: 483–495, 2005.
4. Bergmeyer HU. Methods of Enzymatic Analysis. New York: Academic Press, 1974, vol. 1, p. 474.
5. Blass KA, Schober KE, Li X, Scansen BA, Bonagura JD. Acute Effects of ivabradine on dynamic obstruction of the left ventricular outflow tract in cats with preclinical hypertrophic cardiomyopathy. J Vet Intern Med 28: 838–46, 2014.
6. Boushel R, Gnaiger E, Schjerling P, Skovbro M, Kraunsoe R, Dela F. Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle. Diabetologia 50: 790–796, 2007.
7. Brown S, Atkins C, Bagley R, Carr A, Cowgill L, Davidson M, Egner B, Elliott J, Henik R, Labato M, Littman M, Polzin D, Ross L, Snyder P, Stepien R. Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med 21: 542–558, 2007.
8. Bulteau AL, O’Neill HA, Kennedy MC, Ikeda-Saito M, Isaya G, Szweda LI. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 305: 242–245, 2004.
9. Christiansen LB, Dela F, Koch J, Yokota T. Tissue-specific and substrate- specific mitochondrial bioenergetics in feline cardiac and skeletal muscles. J Vet Med Sci. 2015 Feb 11. [Epub ahead of print]
10. Di Domenico M, Casadonte R, Ricci P, Santini M, Frati G, Rizzo A, Carratelli CR, Lamberti M, Parrotta E, Quaresima B, Faniello CM, Costanzo F, Cuda G. Cardiac and skeletal muscle expression of mutant-myosin heavy chains, degree of functional impairment and phenotypic heterogeneity in hypertrophic cardiomyopathy. J Cell Physiol 227: 3471–3476, 2012.
11. Dimitrow PP, Undas A, Wolkow P, Tracz W, Dubiel JS. Enhanced oxidative stress in hypertrophic cardiomyopathy. Pharmacol Rep 61: 491–495, 2009.
12. Ferasin L, Sturgess CP, Cannon MJ, Caney SM, Gruffydd-Jones TJ, Wotton PR. Feline idiopathic cardiomyopathy: a retrospective study of 106 cats (1994–2001). J Feline Med Surg 5: 151–159, 2003.
13. Fox PR, Liu SK, Maron BJ. Echocardiographic assessment of spontaneously occurring feline hypertrophic cardiomyopathy. An animal model of human disease. Circulation 92: 2645–2651, 1995.
14. Frenneaux MP, Porter A, Caforio AL, Odawara H, Counihan PJ, McKenna WJ. Determinants of exercise capacity in hypertrophic cardiomyopathy. J Am Coll Cardiol 13: 1521–1526, 1989.
15. Godiksen MT, Granström S, Koch J, Christiansen M. Hypertrophic cardiomyopathy in young Maine Coon cats caused by the p.A31P cMyBP-C mutation–the clinical significance of having the mutation. Acta Vet Scand 53: 7, 2011.
16. Granström S, Nyberg Godiksen MT, Christiansen M, Pipper CB, Willesen JL, Koch J. Prevalence of hypertrophic cardiomyopathy in a cohort of British shorthair cats in Denmark. J Vet Intern Med 25: 866–871, 2011.
17. Gundler S, Tidholm A, Häggstrom J. Prevalence of myocardial hypertrophy in a population of asymptomatic Swedish Maine coon cats. Acta Vet Scand 50: 22, 2008.
18. Hey-Mogensen M, Hojlund K, Vind BF, Wang L, Dela F, Beck- Nielsen H, Fernstrom M, Sahlin K. Effect of physical training on mitochondrial respiration and reactive oxygen species release in skeletal muscle in patients with obesity and type 2 diabetes. Diabetologia 53: 1976–1985, 2010.
19. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Arimura K, Egashira K, Takeshita A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85: 357–363, 1999.
20. Inoue T, Ide T, Yamato M, Yoshida M, Tsutsumi T, Andou M, Utsumi H, Tsutsui H, Sunagawa K. Time-dependent changes of myocardial and systemic oxidative stress are dissociated after myocardial infarction. Free Radic Res 43: 37–46, 2009.
21. Jung WI, Sieverding L, Breuer J, Hoess T, Widmaier S, Schmidt O, Bunse M, van Erckelens F, Apitz J, Lutz O, Dietze GJ. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 97: 2536–2542, 1998.
22. Kalsi KK, Smolenski RT, Pritchard RD, Khaghani A, Seymour AM, Yacoub MH. Energetics and function of the failing human heart with dilated or hypertrophic cardiomyopathy. Eur J Clin Invest 29: 469–477, 1999.
23. Kittleson MD, Meurs KM, Munro MJ, Kittleson JA, Liu SK, Pion PD, Towbin JA. Familial hypertrophic cardiomyopathy in maine coon cats: an animal model of human disease. Circulation 99: 3172–3180, 1999.
24. Kowaltowski AJ, de Souza-Pinto NC, Castilho RF, Vercesi AE. Mitochondria and reactive oxygen species. Free Radic Biol Med 47: 333–343, 2009.
25. Kwon SH, Pimentel DR, Remondino A, Sawyer DB, Colucci WS. H2O2 regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways. J Mol Cell Cardiol 35: 615–621, 2003.
26. Larsen S, Nielsen J, Hansen CN, Nielsen LB, Wibrand F, Stride N, Schroder HD, Boushel R, Helge JW, Dela F, Hey-Mogensen M. Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects. J Physiol 590: 3349–3360, 2012.
27. Lemieux H, Semsroth S, Antretter H, Hofer D, Gnaiger E. Mitochondrial respiratory control and early defects of oxidative phosphorylation in the failing human heart. Int J Biochem Cell Biol 43: 1729–1738, 2011.
28. Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J, Hoppel CL. Mitochondrial dysfunction in cardiac disease: ischemia-reperfusion, aging, and heart failure. J Mol Cell Cardiol 33: 1065–1089, 2001.
29. Lin CS, Liu CY, Sun YL, Chang LC, Chiu YT, Huang SY, Lin JH, Yang PC, Chu R, Huang MC, Mao SJ. Alteration of endogenous antioxidant enzymes in naturally occurring hypertrophic cardiomyopathy. Biochem Mol Biol Int 43: 1253–1263, 1997.
30. Lombardi R, Rodriguez G, Chen SN, Ripplinger CM, Li W, Chen J, Willerson JT, Betocchi S, Wickline SA, Efimov IR, Marian AJ. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation 119: 1398–1407, 2009.
31. Lucas DT, Aryal P, Szweda LI, Koch WJ, Leinwand LA. Alterations in mitochondrial function in a mouse model of hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 284: H575–H583, 2003.
32. Marian AJ, Senthil V, Chen SN, Lombardi R. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol 47: 827–834, 2006.
33. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 287: 1308–1320, 2002.
34. Matsushima S, Kuroda J, Ago T, Zhai P, Park JY, Xie LH, Tian B, Sadoshima J. Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy. Circ Res 112: 651–663, 2013.
35. Melacini P, Basso C, Angelini A, Calore C, Bobbo F, Tokajuk B, Bellini N, Smaniotto G, Zucchetto M, Iliceto S, Thiene G, Maron BJ. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J 31: 2111–2123, 2010.
36. Meurs KM, Norgard MM, Ederer MM, Hendrix KP, Kittleson MD. A substitution mutation in the myosin binding protein C gene in ragdoll hypertrophic cardiomyopathy. Genomics 90: 261–264, 2007.
37. Meurs KM, Sanchez X, David RM, Bowles NE, Towbin JA, Reiser PJ, Kittleson JA, Munro MJ, Dryburgh K, Macdonald KA, Kittleson MD. A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy. Hum Mol Genet 14: 3587–3593, 2005.
38. Nakamura K, Kusano KF, Matsubara H, Nakamura Y, Miura A, Nishii N, Banba K, Nagase S, Miyaji K, Morita H, Saito H, Emori T, Ohe T. Relationship between oxidative stress and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Card Fail 11: 117–123, 2005.
39. Neely JR, Rovetto MJ, Oram JF. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 15: 289–329, 1972.
40. Okita K, Yonezawa K, Nishijima H, Hanada A, Ohtsubo M, Kohya T, Murakami T, Kitabatake A. Skeletal muscle metabolism limits exercise capacity in patients with chronic heart failure. Circulation 98: 1886–1891, 1998.
41. Okizaki A, Shuke N, Sato J, Sasaki T, Hasebe N, Kikuchi K, Aburano T. A compartment model analysis for investigation of myocardial fatty acid metabolism in patients with hypertrophic cardiomyopathy. Nucl Med Commun 28: 726–735, 2007.
42. Riesen SC, Kovacevic A, Lombard CW, Amberger C. Prevalence of heart disease in symptomatic cats: an overview from 1998 to 2005. Schweiz Arch Tierheilkd 149: 65–71, 2007.
43. Seidman CE, Seidman JG. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. Circ Res 108: 743–750, 2011.
44. Srere PA. Citrate synthase. Methods Enzymol 13: 3–11, 1969.
45. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85: 1093–1129, 2005.
46. Steinberg SF. Oxidative stress and sarcomeric proteins. Circ Res 112: 393–405, 2013.
47. Stride N, Larsen S, Hey-Mogensen M, Sander K, Lund JT, Gustafsson F, Kober L, Dela F. Decreased mitochondrial oxidative phosphorylation capacity in the human heart with left ventricular systolic dysfunction. Eur J Heart Fail 15: 150–157, 2012.
48. Tadamura E, Kudoh T, Hattori N, Inubushi M, Magata Y, Konishi J, Matsumori A, Nohara R, Sasayama S, Yoshibayashi M, Tamaki N. Impairment of BMIPP uptake precedes abnormalities in oxygen and glucose metabolism in hypertrophic cardiomyopathy. J Nucl Med 39: 390–396, 1998.
49. Tonkonogi M, Sahlin K. Rate of oxidative phosphorylation in isolated mitochondria from human skeletal muscle: effect of training status. Acta Physiol Scand 161: 345–353, 1997.
50. Tretter L, Ambrus A. Measurement of ROS homeostasis in isolated mitochondria. Methods Enzymol 547: 199–223, 2014.
51. Unno K, Isobe S, Izawa H, Cheng XW, Kobayashi M, Hirashiki A, Yamada T, Harada K, Ohshima S, Noda A, Nagata K, Kato K, Yokota M, Murohara T. Relation of functional and morphological changes in mitochondria to myocardial contractile and relaxation reserves in asymptomatic to mildly symptomatic patients with hypertrophic cardiomyopathy. Eur Heart J 30: 1853–1862, 2009.
52. Votyakova TV, Reynolds IJ. m-dependent and -independent production of reactive oxygen species by rat brain mitochondria. J Neurochem 79: 266–277, 2001.
53. Wang L, Seidman JG, Seidman CE. Narrative review: harnessing molecular genetics for the diagnosis and management of hypertrophic cardiomyopathy. Ann Intern Med 152: 513–520, W181, 2010.
54. Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. N Engl J Med 364: 1643–1656, 2011.
55. Wess G, Maurer J, Simak J, Hartmann K. Use of Simpson’s method of disc to detect early echocardiographic changes in Doberman Pinschers with dilated cardiomyopathy. J Vet Intern Med 24: 1069–1076, 2010.
56. Wojtczak L, Schonfeld P. Effect of fatty acids on energy coupling processes in mitochondria. Biochim Biophys Acta 1183: 41–57, 1993.
57. Xu X, Hu X, Lu Z, Zhang P, Zhao L, Wessale JL, Bache RJ, Chen Y. Xanthine oxidase inhibition with febuxostat attenuates systolic overloadinduced left ventricular hypertrophy and dysfunction in mice. J Card Fail 14: 746–753, 2008.